Dengue Literature Review

Aringer2019 - 2019 EULAR ACR SLE Classification Criteria

4 min read

Aringer2019 - 2019 EULAR ACR SLE Classification Criteria

Full citation: Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology 2019. DOI: 10.1002/art.40930.

Raw file: [[raw/aringer2019.pdf]]

Summary

This landmark paper describes the development and validation of the 2019 EULAR/ACR classification criteria for SLE, replacing the 1997 ACR and 2012 SLICC criteria. It was developed through a four-phase international initiative involving over 200 SLE experts, methodologists, and patient advocates, using both expert-consensus (Delphi exercises, nominal group technique, multicriteria decision analysis) and data-driven approaches across derivation (n=1,001) and validation (n=1,270) cohorts from 21 international centres.

The defining structural innovation is the use of a positive ANA (≥1:80 on HEp-2 cells, or equivalent) as a mandatory entry criterion: patients who have never tested ANA-positive cannot be classified as SLE under this system. The remaining criteria are additive and weighted across 10 domains (7 clinical, 3 immunologic); a total score ≥10 classifies as SLE.

Study Design

  • Type: Multi-phase international classification criteria development and validation study
  • Sample size: Derivation cohort: 501 SLE + 500 controls; validation cohort: 696 SLE + 574 controls; 21 international centres
  • Setting: Academic rheumatology centres across North America, Europe, Asia, Latin America
  • Population: Adults with SLE or conditions mimicking SLE; enriched for early disease (<12 months); predominantly female (~89%), mean age 45 ± 14 years

Key Findings

  • ANA as entry criterion: A systematic literature review of 13,080 SLE patients (64 studies) found ANA ≥1:80 on HEp-2 cells has sensitivity of 97.8% (95% CI 96.8–98.5%) for SLE; 99.5% of early SLE patients in phase I cohort were ANA positive
  • Final criteria performance (validation cohort): Sensitivity 96.1%, specificity 93.4% — superior to 1997 ACR (82.8%/93.4%) and SLICC 2012 (96.7%/83.7%)
  • Criterion weights (simplified): highest-weight item is class III/IV lupus nephritis (10 points); acute cutaneous lupus/musculoskeletal involvement (6 points each); ANA alone does not contribute additive points — it is only an entry gate
  • ANA definition: ANA at a titer of ≥1:80 on HEp-2 cells or equivalent positive test at least once (historical positive counts); IIF on HEp-2 or solid-phase ANA screening immunoassay with equivalent performance is “highly recommended”
  • 58% of SLE experts in the Delphi exercise were uncomfortable classifying SLE without a positive ANA; an additional 19% were uncertain
  • A small subset of ANA-negative SLE patients does exist and cannot be classified under these criteria — identified as an important research gap

Methods Used

  • Indirect Immunofluorescence ANA Test (HEp-2 substrate, ≥1:80; definition used for entry criterion)
  • Multicriteria decision analysis (1000Minds software; pairwise criteria comparisons by 17-expert panel)
  • Systematic literature review with meta-regression for ANA operating characteristics
  • Delphi exercise (147 international experts, 3 rounds)

Entities Mentioned

(None specific to dengue)

Concepts Addressed

  • Antinuclear Antibodies (central role: ANA ≥1:80 as mandatory SLE entry criterion; sensitivity data; clinical threshold justification)
  • Autoimmunity in Dengue (indirectly relevant: establishes the clinical significance of the ANA threshold used in population studies contextualising post-dengue autoimmunity)

Relevance & Notes

This paper is not an ANA prevalence study but is included in this wiki because it formalises the clinical threshold (ANA ≥1:80 on HEp-2 cells) that defines the boundary between clinically significant and subclinical ANA positivity. All population prevalence data in Satoh2012 - ANA Prevalence in United States and Dinse2022 - Increasing ANA Prevalence in United States use 1:80 as their testing dilution — the same threshold validated here as the SLE entry criterion.

In the dengue context: Garcia2009 - Long-term Clinical Symptoms Post-Dengue found 23.1% ANA positivity in post-dengue symptomatic patients. If the testing dilution in that study approximated 1:80 or 1:160, then comparing against the ~14% healthy-population rate at 1:80 (Satoh2012) or 5% at 1:160 (Tan1997) suggests genuine elevation. The Aringer2019 criteria also confirm that ANA at this threshold, while highly sensitive for SLE, is not specific — a fact critical to interpreting elevated ANA in post-dengue patients who may not have SLE.

Limitations: Criteria developed in academic centre populations enriched for early disease; performance in community practice, paediatric SLE, and some ethnic minority groups requires further validation.

Questions Raised

  • Do post-dengue patients who test ANA-positive meet any additional EULAR/ACR 2019 weighted criteria, which would further support a true autoimmune process rather than low-titer nonspecific positivity?
  • What is the natural history of ANA positivity in post-dengue patients — does it resolve, persist, or progress toward meeting formal SLE classification criteria over time?

Graph View

Backlinks